Financial Daily from THE HINDU group of publications
Thursday, May 27, 2004

Cross Currency

Group Sites

Corporate - Research & Development
Industry & Economy - Health

Delays hit clinical trials of India-specific AIDS vaccine

P.T. Jyothi Datta

Mumbai , May 26

ANOTHER cycle of delays has pushed clinical trials on the India-specific AIDS vaccine being developed by the International Aids Vaccine Initiative (IAVI) to the end of 2004 or early-2005.

Even though the project has identified three vaccine candidates to be developed in India - inadequate toxicology data has pushed the commencement of clinical trials on the MVA vaccine to later this year, Mr Mark Chataway, IAVI's Team Leader-India, told Business Line.

The Indian Council of Medical Research (ICMR) is partnering the project with IAVI and after a couple of time overruns, the phase-I clinical trial on the vaccine was eventually set to commence at Pune's NARI institute in July this year.

"Delays happen in science. We will have to give more data on the studies conducted on animals and documents are likely to be submitted to the Drug Controller General of India (DCGI) in a few months," he said.

Meanwhile, one of the three other vaccine candidates will also be put up for approvals and could go in for phase-I trials, subject to getting the necessary clearance soon enough, he said. Phase-I trials involve about 50-100 human volunteers who would be given the vaccine.

"But under no circumstance will a healthy volunteer be injected with the AIDS virus or develop the illness as a result of participating in the clinical trial," he stated, in an effort to allay the fears that abound around the AIDS-vaccine trials.

"Tiny fragments of the virus are injected in a disguised form. These fragments will not recombine to from the virus, so the fear in this case is unfounded," he added.

Meanwhile, ICMR had called for local pharma companies to participate in the project and support later stages of vaccine-trial by producing the vaccines locally.

"Eight companies had applied and the issue is currently undergoing negotiations at a commercial stage. Vaccines for phase-I trials would be developed by the US-based Therion Biologics. But as the vaccine goes into future trials, the technology would be transferred to an Indian company that has been identified by the Indian Government," he said.

On whether the delay has caused a cost overrun, he said that IAVI had earmarked funds for the early development of the vaccine.

"The big question is with regard to the later stage of vaccine development. If an AIDS vaccine is developed, then how it would be made affordable to the poor, for instance, is another issue. We are working on a contingent purchase fund, with donations from industrialised nations, besides looking at other alternate mechanisms," he said.

More Stories on : Research & Development | Health | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Delays hit clinical trials of India-specific AIDS vaccine

USFDA clearance for Sun Pharma plants
Balaji Tele to boost regional sponsored programmes
Hewitt to include blue-collar workers in `Best Employer' survey
Alstom India bags Renusagar's Rs 70-cr upgrade order
`Investor protection to be vital part of Companies Act'
Bombay HC okays cut in VSNL premium account
Blue Star bags Rs 9-cr order for Delhi airport
Thermax to buy out minority stake in Babcock joint venture — Sales up at Rs 603.81 cr
Schwing Stetter to double capacity
GMR Ind profit up 276 pc; plans Rs 60-cr expansion
Orchid inks deal with Par for US marketing
Abhinav Outsourcing in tie-up with Canadian varsities
Suryalakshmi Cotton plans expansion
Pvt firms top in PSU debt placements

The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright 2004, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line